Maximilian Merz: A comeback of checkpoint inhibition in Multiple Myeloma
Maximilian Merz, Head of Early Clinical Trials Unit Leipzig (ECTUL) at Leipzig University, shared a post on LinkedIn:
“Please check my latest article in Nature Cancer on A comeback of checkpoint inhibition in Multiple Myeloma.We all remember the disappointment of PD1 blockade in combination with IMiDs for newly diagnosed and relapsed/refractory Myeloma.
In their new article from Madhav Dhodapkar‘s group, Shambavi Richard, Alexander Lesokhin and Barry Paul report on the positive effects of TIGIT-LAG3 blockade in RRMM.
They describe long term remissions and destinct changes in the immune microenvironemnt upon combination of anti-LAG3 or anti-TIGIT antibodies in combination with pomalidomide.
In my commentary, I argued that this might pave the way for new studies with novel immune checkpoint inhibitors especially in the context of bispecific antibodies and CAR T-cells.Who would not love to see PD1-LAG3-TIGIT blockade before apheresis to get T-cells ready for manufacturing or as early maintenance after infusion to keep them going?!So much more to come and interesting study.”
Title: A comeback for checkpoint inhibition in multiple myeloma
Author: Maximilian Merz
Source:Maximilian Merz/LinkedIn
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023